Brief: Jiangsu Recbio Technology Says It Got Clinical Trial Approval For REC610 In Philippines
19/12/2022 08:15
Dec 19 (Reuters) - Jiangsu Recbio Technology Co Ltd
2179.HK :
* GOT CLINICAL TRIAL APPROVAL FOR NOVEL ADJUVANTED
RECOMBINANT
SHINGLES VACCINE REC610 IN PHILIPPINES
* RECEIVED CLINICAL TRIAL APPROVAL FROM FOOD AND DRUG
ADMINISTRATION OF PHILIPPINES
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares